SFY 2020 - 2021 MC MLR Summary
HIV SNP line of business
- Report also available in Portable Document Format (PDF)
| SFY 2020 - 2021 MC MLR Summary | |||||||
|---|---|---|---|---|---|---|---|
| HIV SNP line of business | |||||||
| Plan | MLR AFTER Credibility Adjustment |
Medical Expense (Total Numerator) |
Premium (Total Denominator) |
Remittance | Credible | MMs | |
| Amida Care Inc. | 90.29% | $412,000,191 | $466,659,775 | $0 | Partially Credible | 96,212 | |
| MetroPlus Health Plan, Inc | 95.84% | $208,386,697 | $224,081,467 | $0 | Partially Credible | 51,190 | |
| VNS (d/b/a VNSNY Choice) and Subsidiary | 95.90% | $175,661,970 | $190,079,238 | $0 | Partially Credible | 35,276 | |
| Total | $796,048,858 | $880,820,481 | $0 | 182,678 | |||
NOTES:
Please note that the Remittance is for this line of business for one year ONLY based on a MLR Target of 86%.
No remittance for plan if Non-Credible
